Intravenous Immunoglobulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The intravenous immunoglobulin market was valued at approximately USD 10,183.35 million in 2020, and it is expected to witness a revenue of USD 15,344.93 million by 2026, with a CAGR of 7.13% over the forecast period (2021-2026).

The outbreak of the COVID-19 pandemic is expected to have a positive impact on the growth of the intravenous immunoglobulin market globally. According to the research article published in the Journal of Allergy and Clinical Immunology, 2020, the United Kingdom Primary Immunodeficiency Network had documented the impact of COVID-19 infection on primary immunodeficiency disease (PID) and symptomatic secondary immunodeficiency (SID) individuals. The study revealed that out of 100 individuals with PID, SID, autoinflammatory diseases, and C1 inhibitor deficiency, 70% of the individuals were infected with the SARS-CoV2 virus, and 59% were admitted to hospitals, with 8% being admitted to intensive care units. Thus, as immune-deficient individuals are at higher risk of being infected with COVID-19, the market for immunoglobulin therapies is expected to grow during the pandemic. Additionally, as per the research article published in BMC Infectious Diseases, 2020, the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to improve the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Thus, owing to the aforementioned factors, the studied market is expected to witness healthy growth during the pandemic era.

Intravenous immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions, including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and certain other infections. Depending on the formulation, it can be injected into the muscle, a vein, or under the skin.

An increase in the geriatric population and the prevalence of immunodeficiency disorders and bleeding disorders have increased the demand for novel intravenous immunoglobulin therapies. This has led to an increase in the adoption rate of these therapies. Hence, these factors have helped the market growth. However, stringent regulatory approval processes and regulations and the high cost of therapy have been restraining the growth of the market.

Scope of the Report

Intravenous immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions, including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and certain other infections. Depending on the formulation, it can be injected into a muscle, a vein, or under the skin. The intravenous immunoglobulin market is segmented by type (IgG, IgA, IgM, Ig E, and IgD), application (hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (USD million) for all the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Primary Immunodeficiency Diseases Segment is Expected to Register a High CAGR Over the Forecast Period

The primary immunodeficiency diseases segment is expected to witness healthy growth over the forecast period. According to the research article published in Frontiers in Immunology, 2020, the incidence of primary immunodeficiency diseases (PIDs) is 1 in 10,000 population globally, and the majority of PIDs are presented in early childhood. Additionally, as per the research article titled "Systematic Review of Primary Immunodeficiency Diseases in Malaysia: 1979–2020", published in Frontiers in Immunology, 2020, approximately six million people are predicted to be living with PIDs globally, among which only 27,000–60,000 cases were diagnosed. The incidence of PIDs in Singapore was observed to be 2.65 per 100,000 live births and an estimated occurrence rate of one in 37,000 live births, as per the above-mentioned source. Hence, the growing burden of PIDs globally is expected to drive the studied segment’s growth over the forecast period.

Intravenous immunoglobulin (IVIG) therapy has been used in primary immunodeficiency diseases (PI) and other immune deficiency disorders. There are several specific medical therapies available for people with PIDs with antibody deficiency, which account for more than half of the primary immunodeficiencies. These illnesses, such as common variable immune deficiency (CVID), X-linked agammaglobulinemia (XLA), and other disorders, are characterized by a lack of and/or impaired antibody function. In October 2019, ADMA Biologics began the first commercial sales of ASCENIV, a plasma-derived polyclonal human immune globulin product indicated for the treatment of primary immunodeficiency diseases in adults and adolescents, which received US FDA approval in April 2019.

Hence, with the availability of IVIG therapies and the advancements in intravenous immunoglobulin products to treat the highly prevalent primary immunodeficiency diseases, the studied segment is expected to grow significantly over the coming years.

To understand key trends, Download Sample Report